Summary
Plasma concentrations of pirprofen and of its pyrrol metabolite were assessed in 9 elderly patients (3 males, 6 females; mean age 76 years) suffering from chronic degenerative disease. Pirprofen 400 mg in 4 ml was administered i.m. and the pharmacokinetic profile of the drug and the metabolite was calculated.
The AUC, Cmax and t1/2 of pirprofen were similar to those found in previous studies, and, as expected, those parameters for the pyrrol metabolite were lower (Cmax=2.8 µg/ml−1; tmax=6.4 h; AUC(0–32)=56.5 µg · h · ml−1). One patient (n=8) showed different pharmacokinetic behaviour, which is discussed.
The data suggest that age has little influence on the pharmacokinetic of pirprofen, although unpredictable responses should always be considered in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cuny G, Royer RJ, Muir JM, Serot JM, Faure G, Netter P, Maillard A, Penin F (1979) Pharmacokinetics of salicylates in the elderly. Gerontology 25: 49–55
Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, Horgan J (1979) Digoxin in the elderly: Pharmacokinetic consequences of old age. Clin Pharmacol Ther 25: 772–776
Fulton B, James OFW, Rawlins MD (1979) The influence of age on the pharmacokinetics of paracetamol. Br J Clin Pharmacol 6: 418–420
Mason RW, McQueen EG (1974) Protein binding of indomethacin: Binding of indomethacin to human albumin and its displacement from binding by ibuprofen, phenylbutazone, and salicylate in vitro. Pharmacology 12: 12–19
Kampmann JP, Molholm-Hansen JE (1979) Renal excretion of drugs. In: Crooks J (ed) Drugs and the elderly. University Park, McMillan Press, London, pp 77–87
Mooney H, Roberts R, Cooksley W, Crooksley WG, Halliday JW, Powell LW (1985) Alterations in the liver with ageing. Clin Gastroenterol 14: 757–771
Schneider RE, Bishop H, Yates RA, Quarterman CP, Kendall MJ (1980) Effects of age on plasma propranolol levels. Br J Clin Pharmacol 10: 169–170
Crook PR, Willis JV, Kendall MJ, Jack DB, Fowler PD (1982) The above pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease. Eur J Clin Pharmacol 21: 331–334
Colussi D, Marfil F, Sioufi A (1985) Simultaneous determination of pirprofen and its metabolite, the pyrrol derivative, in plasma by high performance liquid chromatography. J Chromatogr Biomed Appl 339: 157–162
Rooney L, Kendall MJ, Main A, Hosie J, John VA (1985) Pharmacokinetics of pirprofen in young volunteers and elderly patients. Eur J Clin Pharmacol 29: 73–77
Todd PA, Beresford R (1986) Pirprofen: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 32: 509–537
Gum OB, Luders RC (1981) The pharmacokinetics of pirprofen. Curr Ther Res 30: S118-S122
Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R (1975) Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 18: 425–432
Castleden CM, George CF, Marcer D, Hallett C (1977) Increased sensitivity to nitrazepam in old age. Br Med J 1: 10–12
Schneider RE, Bishop H, Kendall MJ, Quarterman CP (1981) Effect of inflammatory disease on plasma concentrations of three beta-adrenoceptor blocking drugs. Int J Clin Pharmacol Ther Toxicol 19: 158–162
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rossi, F.A., Ferrero, M., Balladore, G.E. et al. Pharmacokinetics of pirprofen and its pyrrol metabolite in elderly patients. Eur J Clin Pharmacol 35, 379–383 (1988). https://doi.org/10.1007/BF00561368
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561368